Intranasal pirodavir significantly reduced rhinovirus shedding on day 3 (70% vs 23%, P<0.001) but provided no clinical benefit in resolving respiratory symptoms or reducing illness duration compared to placebo.
RCT (n=201)
Double-blind
Randomly assigned
No
Does intranasal pirodavir improve symptom resolution in adults with naturally occurring rhinovirus colds?
Intranasal pirodavir significantly reduces rhinovirus shedding but provides no clinical benefit in resolving symptoms of naturally occurring colds.
Absolute Event Rate: 7% vs 7%
A randomized, double-blind, placebo-controlled trial assessed the therapeutic efficacy of intranasal pirodavir in naturally occurring rhinovirus colds. Adults with symptoms of < or = 2 days' duration were randomly assigned to intranasal sprays of pirodavir (2 mg per treatment) or placebo six times daily for 5 days. In people with laboratory-documented rhinovirus colds (53 in the pirodavir group, 55 in the placebo group), no significant differences in the resolution of respiratory symptoms were apparent between the groups. The median duration of illness was 7 days in each group. Similarly, scores for individual symptoms found no differences in favor of pirodavir during or after treatment. In contrast, reduced frequencies of rhinovirus shedding were observed in the pirodavir group on day 3 (70 versus 23%; P < 0.001) and day 5 (38 versus 12%; P = 0.002) but not after the cessation of treatment, on day 7 (19 versus 21%). No pirodavir-resistant viruses were recovered from treated individuals. The pirodavir group had higher rates of nasal dryness, blood in mucus, or unpleasant taste on several study days. In summary, intranasal sprays of pirodavir were associated with significant antiviral effects but no clinical benefit in treating naturally occurring rhinovirus colds.
Hayden et al. (Wed,) conducted a rct in Naturally occurring rhinovirus colds (n=201). Intranasal pirodavir vs. Placebo was evaluated on Median duration of illness (days). Intranasal pirodavir significantly reduced rhinovirus shedding on day 3 (70% vs 23%, P<0.001) but provided no clinical benefit in resolving respiratory symptoms or reducing illness duration compared to placebo.